Your browser doesn't support javascript.
loading
: 20 | 50 | 100
1 - 20 de 212
1.
J Fish Dis ; 44(10): 1579-1586, 2021 Oct.
Article En | MEDLINE | ID: mdl-34152617

Anaesthetics are commonly applied in pharmacokinetic (PK) studies to assure smooth handling of experimental procedures or to promote animal welfare. However, the influence of anaesthetics on the PK of co-administered drug is generally unknown but assumes ignorable. The goal of the study was to investigate the effect of tricaine methanesulfonate (MS-222), 2-phenoxyethanol (2-PE) and eugenol (EUG) on the PK of florfenicol (FF) in Nile tilapia. Twenty-eight fish were repeatedly exposed to 90 ppm EUG, 300 ppm MS-222 or 900 ppm 2-PE before FF oral administration (15 mg/kg) and each successive blood sampling. The serum concentration-time profiles were analysed by a 2-compartmental model, and the generated parameters in the control (without anaesthetic) and anaesthetic groups were statistically compared. The results demonstrated that the serum concentrations of each anaesthetic were similar at every FF sampling times (70 µg/ml for MS-222; 277 µg/ml for 2-PE; and 61 µg/ml for EUG). In comparison with the control group, the repeated use of MS-222 did not result in a statistical difference in most of the PK parameters. In contrast, the elimination half-lives of the 2-PE and EUG groups were significantly longer whereas the absorption and distribution half-lives of the 2-PE group were significantly shorter than the control, resulting in altered optimal dosages in the simulation modelling. Whether or not the numbers and extent of PK parameters change mitigate subsequent estimations of other PK-derived secondary values such as dosing regimen and withdrawal time remains to be elucidated, but the auxiliary use of anaesthetics in PK studies should not assume uninfluential.


Aminobenzoates/administration & dosage , Anesthetics/administration & dosage , Anti-Bacterial Agents/pharmacokinetics , Cichlids/physiology , Ethylene Glycols/administration & dosage , Eugenol/administration & dosage , Thiamphenicol/analogs & derivatives , Animals , Random Allocation , Thiamphenicol/pharmacokinetics
2.
Arch Toxicol ; 95(6): 2019-2036, 2021 06.
Article En | MEDLINE | ID: mdl-33844041

2-Phenoxyethanol (PE), ethylene glycol monophenyl ether, is widely used as a preservative in cosmetic products as well as in non-cosmetics. Since PE has been used in many types of products, it can be absorbed via dermal or inhaled route for systemic exposures. In this study, the pharmacokinetic (PK) studies of PE and its major metabolite, phenoxyacetic acid (PAA), after dermal (30 mg and 100 mg) and inhaled administration (77 mg) of PE in rats were performed. PE was administered daily for 4 days and blood samples were collected at day 1 and day 4 for PK analysis. PE was rapidly absorbed and extensively metabolized to form PAA. After multiple dosing, the exposures of PE and PAA were decreased presumably due to the induction of metabolizing enzymes of PE and PAA. In dermal mass balance study using [14C]-phenoxyethanol ([14C]PE) as a microtracer, most of the PE and its derivatives were excreted in urine (73.03%) and rarely found in feces (0.66%). Based on these PK results, a whole-body physiologically-based pharmacokinetic (PBPK) model of PE and PAA after dermal application and inhalation in rats was successfully developed. Most of parameters were obtained from the literatures and experiments, and intrinsic clearance at steady-state (CLint,ss) were optimized based on the observed multiple PK data. With the developed model, systemic exposures of PE and PAA after dermal application and inhalation were simulated following no-observed-adverse-effect level (NOAEL) of 500 mg/kg/day for dermal application and that of 12.7 mg/kg/day for inhalation provided by the Environmental Protection Agency. The area under the concentration-time curve at steady state (AUCss) in kidney and liver (and lung for inhalations), which are known target organs of exhibiting toxicity of PE, as well as AUCss in plasma of PE and PAA were obtained from the model.


Acetates/pharmacokinetics , Ethylene Glycols/pharmacokinetics , Models, Biological , Administration, Cutaneous , Administration, Inhalation , Animals , Area Under Curve , Ethylene Glycols/administration & dosage , Ethylene Glycols/toxicity , Male , No-Observed-Adverse-Effect Level , Rats , Rats, Sprague-Dawley , Tissue Distribution
3.
PLoS One ; 16(3): e0246504, 2021.
Article En | MEDLINE | ID: mdl-33667238

Zebrafish are frequently used as a means to investigate development. These studies increasingly require repeated anaesthesia of zebrafish during juvenile (i.e. metamorphic) stages. The effects of anaesthesia during this time remain poorly studied. The aim of this study was to develop a reliable method that can be used for frequently repeated anaesthesia during juvenile stages. Initially, we assessed different concentrations of MS-222, the most commonly used fish anaesthetic, for 30 minute anaesthesia with recovery. We showed that suitable MS-222 doses could be identified for the smallest (7mm) and largest (20mm) fish. However, we found that juvenile fish within a specific metamorphic window (sized between 8-16 mm) were vulnerable to MS-222 and no standard concentration of MS-222 provided reliable anaesthesia under these conditions. Hence we focussed our efforts on identifying a protocol for these stages. We tested six different published anaesthesia protocols P1-P6 where P1, P2 corresponds to 0.01% MS-222, P3, P4: 0.085% 2-phenoxyethanol and P5, P6: 0.00025%/0.0050% Propofol/Lidocaine. In protocols P1, P3, P5 fish were maintained by immersion, whilst in P2, P4 and P6: fish were maintained on an anaesthetic-doused cotton-pad. We assessed reliable anaesthesia using 10 fish for 10 minutes, with full recovery. Our data allowed us to eliminate two of these protocols as unsuitable for short term anaesthesia with recovery of juvenile fish. Extending these studies to explore repeated anaesthesia at 4 day intervals for 20 days under the remaining four protocols, we showed that P1 and P4 were both suitable for repeated anaesthesia, and that P4 was most suitable for imaging. We confirmed that P4 remained suitable when the frequency of anaesthesia was increased to every 2 days. We conclude that this protocol provides a refinement to the current protocol for repeated anaesthesia with recovery of juvenile zebrafish in the vulnerable metamorphic window.


Aminobenzoates/administration & dosage , Ethylene Glycols/administration & dosage , Lidocaine/administration & dosage , Propofol/administration & dosage , Zebrafish/growth & development , Anesthesia/methods , Animals , Body Size , Dose-Response Relationship, Drug , Life Cycle Stages , Metamorphosis, Biological
4.
JACC Cardiovasc Imaging ; 13(6): 1325-1336, 2020 06.
Article En | MEDLINE | ID: mdl-32417333

OBJECTIVES: The purpose of this study was to determine phenotypes characterizing cardiac involvement in AL amyloidosis by using direct (fluorine-18-labeled florbetapir {[18F]florbetapir} positron emission tomography [PET]/computed tomography) and indirect (echocardiography and cardiac magnetic resonance [CMR]) imaging biomarkers of AL amyloidosis. BACKGROUND: Cardiac involvement in systemic light chain amyloidosis (AL) is the main determinant of prognosis and, therefore, guides management. The hypothesis of this study was that myocardial AL deposits and expansion of extracellular volume (ECV) could be identified before increases in N-terminal pro-B-type natriuretic peptide or wall thickness. METHODS: A total of 45 subjects were prospectively enrolled in 3 groups: 25 with active AL amyloidosis with cardiac involvement (active-CA), 10 with active AL amyloidosis without cardiac involvement by conventional criteria (active-non-CA), and 10 with AL amyloidosis with cardiac involvement in remission for at least 1 year (remission-CA). All subjects underwent echocardiography, CMR, and [18F]florbetapir PET/CT to evaluate cardiac amyloid burden. RESULTS: The active-CA group demonstrated the largest myocardial AL amyloid burden, quantified by [18F]florbetapir retention index (RI) 0.110 (interquartile range [IQR]: 0.078 to 0.139) min-1, and the lowest cardiac function by global longitudinal strain (GLS), median GLS -11% (IQR: -8% to -13%). The remission-CA group had expanded extracellular volume (ECV) and [18F]florbetapir RI of 0.097 (IQR: 0.070 to 0.124 min-1), and abnormal GLS despite hematologic remission for >1 year. The active-non-CA cohort had evidence of cardiac amyloid deposition by advanced imaging metrics in 50% of the subjects; cardiac involvement was identified by late gadolinium enhancement in 20%, elevated ECV in 20%, and elevated [18F]florbetapir RI in 50%. CONCLUSIONS: Evidence of cardiac amyloid infiltration was found based on direct and indirect imaging biomarkers in subjects without CA by conventional criteria. The findings from [18F]florbetapir PET imaging provided insight into the preclinical disease process and on the basis of interpretation of expanded ECV on CMR and have important implications for future research and clinical management of AL amyloidosis. (Molecular Imaging of Primary Amyloid Cardiomyopathy [MICA]; NCT02641145).


Aniline Compounds/administration & dosage , Cardiomyopathies/diagnostic imaging , Echocardiography, Doppler , Ethylene Glycols/administration & dosage , Fluorine Radioisotopes/administration & dosage , Immunoglobulin Light-chain Amyloidosis/diagnostic imaging , Magnetic Resonance Imaging, Cine , Myocardium/pathology , Positron Emission Tomography Computed Tomography , Radiopharmaceuticals/administration & dosage , Aged , Cardiomyopathies/pathology , Early Diagnosis , Female , Humans , Immunoglobulin Light-chain Amyloidosis/pathology , Male , Middle Aged , Multimodal Imaging , Predictive Value of Tests , Prospective Studies , Severity of Illness Index , United States
5.
Cutan Ocul Toxicol ; 39(2): 134-142, 2020 Jun.
Article En | MEDLINE | ID: mdl-32216482

Aim of the study: Following exposure to toxic chemicals, skin uptake is a potential route of intoxication. Therefore, efficient methods for rapid skin decontamination to mitigate systemic effects are of utmost importance. In operational guidelines, skin decontamination is recommended to be performed by dry absorption and washing with water or soapy water. In the present study, evaluation of decontamination efficacy using water or soapy water was performed for five chemicals, three toxic industrial chemicals and two simulants for chemical warfare agents.Materials and methods: Decontamination was initiated at time points 5, 15, 45 and 120 min after exposure in order to evaluate the time window for efficient decontamination. Experiments were conducted utilizing an in vitro skin penetration model to allow exposure of toxic chemicals on human skin. Results: For all test substances, it was clearly demonstrated that decontamination had greater efficacy when initiated at the earliest time-point while decontamination after 120 min was less efficient. Adding soap to the water showed no significant improvement for any of the tested substances.Conclusion: These results are of reledvance for the development of efficient operational decontamination procedures.


Decontamination/methods , Hazardous Substances/administration & dosage , Soaps/administration & dosage , Water/administration & dosage , Acrylonitrile/administration & dosage , Butylamines/administration & dosage , Chemical Warfare Agents , Ethylene Glycols/administration & dosage , Humans , In Vitro Techniques , Lactates/administration & dosage , Salicylates/administration & dosage , Skin/drug effects , Skin Absorption
6.
Sci Rep ; 10(1): 1209, 2020 Jan 27.
Article En | MEDLINE | ID: mdl-31988350

In this study, the toxic effects of phenoxyethanol (Phy-Et), which is widely used in cosmetic industry, has been investigated with Allium test by means of physiological, cytogenetic, anatomical and biochemical parameters. To determine the changes in physiological reactions weight gain, relative injury rate, germination percentage and root length were investigated. Malondialdehyde, superoxide dismutase, glutathion and catalase levels were analyzed as biochemical parameters for determining the presence of oxidative stress. Mitotic index, micronucleus and chromosomal abnormality frequencies were studied as cytogenetic evaluation and the anatomical changes in root tip cells were investigated by cross sections. Changes in surface polarity and wettability were investigated by taking contact angle measurements of pressed root preparations. The mechanism of toxicity has been tried to be explained by these contact angles and this is the first study using contact angle measurements in toxicity tests. Consequently, exposure to Phy-Et resulted in a decrease in all measured physiological parameters and in mitotic index. In contrast, significant increases in the micronucleus and chromosomal abnormality frequencies were observed and the most significant toxic effect was found in 10 mM Phy-Et treated group. Phy-Et application induced oxidative damage and caused a significant increase in malondialdehyde level and a decrease in glutathione level compared to control group. Also a response occured against oxidative damage in superoxide dismutase and catalase activity and the activities increased in 2.5 mM and 5 mM Phy-Et treated groups and decreased in 10 mM Phy-Et treated groups. Furthermore, Phy-Et treatment resulted in some anatomical damages and changes such as necrosis, cell deformation and thickening of the cortex cell wall in root tip meristem cells of A. cepa. In the contact angle measurements taken against water, it was found that the wettability and hydrophilicity of the root preparations treated with Phy-Et were reduced, and this was the explanation of the growth abnormalities associated with water uptake. As a result, it was found that Phy-Et application caused toxic effects on many viability parameters and A. cepa test material was a reliable biomarker in determining these effects.


Ethylene Glycols/pharmacology , Onions/drug effects , Plant Extracts/pharmacology , Plant Roots/drug effects , Catalase/analysis , Chromosome Aberrations/drug effects , Ethylene Glycols/administration & dosage , Ethylene Glycols/toxicity , Germination/drug effects , Glutathione/analysis , Malondialdehyde/analysis , Mitotic Index , Onions/growth & development , Oxidative Stress/drug effects , Plant Extracts/administration & dosage , Plant Extracts/toxicity , Plant Roots/growth & development , Risk Assessment , Superoxide Dismutase/analysis , Tea/chemistry , Wettability/drug effects
7.
PLoS One ; 14(12): e0226577, 2019.
Article En | MEDLINE | ID: mdl-31877173

Amyloid beta (Aß) plaques aggregation is considered as the "start" of the degenerative process that manifests years before the clinical symptoms appear in Alzheimer's Disease (AD). The aim of this study is to use back propagation neural networks (BPNNs) in 18F-florbetapir PET data for automated classification of four patient groups including AD, late mild cognitive impairment (LMCI), early mild cognitive impairment (EMCI), and significant memory concern (SMC), versus normal control (NC) for early AD detection. Five hundred images for AD, LMCI, EMCI, SMC, and NC, i.e., 100 images for each group, were used from the Alzheimer's Disease Neuroimaging Initiative (ADNI) database. The results showed that the automated classification of NC/AD produced a high accuracy of 87.9%, while the results for the prodromal stages of the disease were 66.4%, 60.0%, and 52.9% for NC/LCMI, NC/EMCI and NC/SMC, respectively. The proposed method together with the image preparation steps can be used for early AD detection and classification with high accuracy using Aß PET dataset.


Alzheimer Disease/diagnostic imaging , Aniline Compounds/administration & dosage , Cognitive Dysfunction/diagnostic imaging , Ethylene Glycols/administration & dosage , Positron-Emission Tomography/methods , Aged , Aged, 80 and over , Databases, Factual , Early Diagnosis , Female , Humans , Image Interpretation, Computer-Assisted , Male , Neural Networks, Computer , Neuroimaging
8.
Kaku Igaku ; 56(1): 127-134, 2019.
Article Ja | MEDLINE | ID: mdl-31554771

OBJECTIVE: Obtaining the information on safety and effectiveness of radiopharmaceutical synthesizer NEPTIS plug - 01 and florbetapir (18F) injection solution synthesized by NEPTIS plug - 01 from the post marketing surveillance study. METHODS: Regarding the safety evaluation, failure of device and adverse events were recorded. Regarding the effectiveness evaluation, we assessed the quality of PET images and the impact on the clinical diagnosis. RESULT: During the study period, 12 patients were enrolled. No adverse event was reported from those 12 patients. Two events in 2 patients were reported as a failure of device (In a subsequent investigation, those failures were thought to be caused by inadequacy of procedure manual, which has been revised now). For the quality of PET images, all 12 cases were "good" or "excellent", regardless of the positive or negative of amyloid plaque. The attending physician's diagnosis was changed in 9 patients following the PET imaging. CONCLUSION: NEPTIS plug-01 and florbetapir (18F) were safe and has a favorable effectiveness profile in 12 patients under daily clinical setting.


Alzheimer Disease/diagnostic imaging , Amyloid beta-Peptides/metabolism , Aniline Compounds/chemical synthesis , Drug Compounding/instrumentation , Ethylene Glycols/chemical synthesis , Product Surveillance, Postmarketing , Radiopharmaceuticals/chemical synthesis , Adult , Aged , Aged, 80 and over , Alzheimer Disease/metabolism , Aniline Compounds/administration & dosage , Aniline Compounds/adverse effects , Ethylene Glycols/administration & dosage , Ethylene Glycols/adverse effects , Female , Humans , Injections , Male , Middle Aged , Plaque, Amyloid , Positron-Emission Tomography , Radiopharmaceuticals/administration & dosage , Radiopharmaceuticals/adverse effects , Safety
9.
Int J Pharm ; 569: 118549, 2019 Oct 05.
Article En | MEDLINE | ID: mdl-31394188

Trial-and-error approach to formulation development is long and costly. With growing time and cost pressures in the pharmaceutical industry, the need for computer-based formulation design is greater than ever. In this project, emulgels were designed and optimized using Formulating for Efficacy™ (FFE) for the topical delivery of ibuprofen. FFE helped select penetration enhancers, design and optimize emulgels and simulate skin penetration studies. pH, viscosity, spreadability, droplet size and stability of emulgels were evaluated. Franz cell studies were performed to test in vitro drug release on regenerated cellulose membrane, drug permeation in vitro on Strat-M® membrane and ex vivo on porcine ear skin, a marketed ibuprofen gel served as control. Emulgels had skin compatible pH, viscosity and spreadability comparable to a marketed emulgel, were opaque and stable at 25 °C for 6 months. Oleyl alcohol (OA), combined with either dimethyl isosorbide (DMI) or diethylene glycol monoethyl ether (DGME) provided the highest permeation in 24 h in vitro, which was significantly higher than the marketed product (p < 0.01). OA + DGME significantly outperformed OA ex vivo (p < 0.05). The computer predictions, in vitro and ex vivo penetration results correlated well. FFE was a fast, valuable and reliable tool for aiding in topical product design for ibuprofen.


Anti-Inflammatory Agents, Non-Steroidal/administration & dosage , Anti-Inflammatory Agents, Non-Steroidal/chemistry , Ibuprofen/administration & dosage , Ibuprofen/chemistry , Skin Absorption , Animals , Chemistry, Pharmaceutical , Computer Simulation , Drug Compounding , Ethylene Glycols/administration & dosage , Ethylene Glycols/chemistry , Fatty Alcohols/administration & dosage , Fatty Alcohols/chemistry , In Vitro Techniques , Isosorbide/administration & dosage , Isosorbide/analogs & derivatives , Isosorbide/chemistry , Skin/metabolism , Solubility , Swine
10.
JACC Cardiovasc Imaging ; 12(7 Pt 1): 1165-1173, 2019 07.
Article En | MEDLINE | ID: mdl-30121266

OBJECTIVES: This study sought to test whether relative apical sparing (RELAPS) of left ventricular (LV) longitudinal strain (LS) in cardiac amyloidosis (CA) is explained by regional differences in markers of amyloid burden (18F-florbetapir uptake by positron emission tomography [PET] and/or extracellular volume fraction [ECV] by cardiac magnetic resonance (CMR)]. BACKGROUND: Further knowledge of the pathophysiological basis for RELAPS can help understand the adverse outcomes associated with apical LS impairment. METHODS: This was a prospective study of 32 subjects (age 62 ± 7 years; 50% males) with light chain CA. All subjects underwent two-dimensional echocardiography for LS estimation and 18F-florbetapir PET for quantification of LV florbetapir retention index (RI). A subset also underwent CMR (n = 22) for ECV quantification. Extracellular LV mass (LV mass*ECV) and total florbetapir binding (extracellular LV mass*florbetapir RI) were also calculated. All parameters were measured globally and regionally (base, mid, and apex). RESULTS: There was a significant base-to-apex gradient in LS (-7.4 ± 3.2% vs. -8.6 ± 4.0% vs. -20.8 ± 6.6%; p < 0.0001), maximal LV wall thickness (15.7 ± 1.9 cm vs. 15.4 ± 2.9 cm vs. 10.1 ± 2.4 cm; p < 0.0001), and LV mass (74.8 ± 21.2 g vs. 60.8 ± 17.3 g vs. 23.4 ± 6.2 g; p < 0.0001). In contrast, florbetapir RI (0.089 ± 0.03 µmol/min/g vs. 0.097 ± 0.03 µmol/min/g vs. 0.085 ± 0.03 µmol/min/g; p = 0.45) and ECV (0.53 ± 0.08 vs. 0.49 ± 0.08 vs. 0.49 ± 0.07; p = 0.15) showed no significant base-to-apex gradient in the tissue concentration or proportion of amyloid infiltration, whereas markers of total amyloid load, such as total florbetapir binding (3.4 ± 1.7 µmol/min vs. 2.8 ± 1.5 µmol/min vs. 0.93 ± 0.49 µmol/min; p < 0.0001) and extracellular LV mass (40.0 ± 15.6 g vs. 30.2 ± 10.9 g vs. 11.6 ± 3.9 g; p < 0.0001), did show a marked base-to-apex gradient. CONCLUSIONS: Segmental differences in the distribution of the total amyloid mass, rather than the proportion of amyloid deposits, appear to explain the marked regional differences in LS in CA. Although these 2 matrices are clearly related concepts, they should not be used interchangeably.


Amyloid/analysis , Amyloidosis/diagnostic imaging , Cardiomyopathies/diagnosis , Magnetic Resonance Imaging, Cine , Myocardium/pathology , Positron-Emission Tomography , Stroke Volume , Ventricular Function, Left , Aged , Amyloidosis/pathology , Amyloidosis/physiopathology , Aniline Compounds/administration & dosage , Cardiomyopathies/pathology , Cardiomyopathies/physiopathology , Echocardiography , Ethylene Glycols/administration & dosage , Female , Humans , Male , Middle Aged , Myocardium/chemistry , Predictive Value of Tests , Prospective Studies , Radiopharmaceuticals/administration & dosage
11.
J Cereb Blood Flow Metab ; 39(12): 2419-2432, 2019 12.
Article En | MEDLINE | ID: mdl-30182792

Pharmacokinetic modelling on dynamic positron emission tomography (PET) data is a quantitative technique. However, the long acquisition time is prohibitive for routine clinical use. Instead, the semi-quantitative standardised uptake value ratio (SUVR) from a shorter static acquisition is used, despite its sensitivity to blood flow confounding longitudinal analysis. A method has been proposed to reduce the dynamic acquisition time for quantification by incorporating cerebral blood flow (CBF) information from arterial spin labelling (ASL) magnetic resonance imaging (MRI) into the pharmacokinetic modelling. In this work, we optimise and validate this framework for a study of ageing and preclinical Alzheimer's disease. This methodology adapts the simplified reference tissue model (SRTM) for a reduced acquisition time (RT-SRTM) and is applied to [18F]-florbetapir PET data for amyloid-ß quantification. Evaluation shows that the optimised RT-SRTM can achieve amyloid burden estimation from a 30-min PET/MR acquisition which is comparable with the gold standard SRTM applied to 60 min of PET data. Conversely, SUVR showed a significantly higher error and bias, and a statistically significant correlation with tracer delivery due to the influence of blood flow. The optimised RT-SRTM produced amyloid burden estimates which were uncorrelated with tracer delivery indicating its suitability for longitudinal studies.


Alzheimer Disease , Amyloid beta-Peptides/metabolism , Aniline Compounds , Cerebrovascular Circulation , Ethylene Glycols , Models, Cardiovascular , Positron-Emission Tomography , Alzheimer Disease/diagnostic imaging , Alzheimer Disease/metabolism , Alzheimer Disease/physiopathology , Aniline Compounds/administration & dosage , Aniline Compounds/pharmacokinetics , Ethylene Glycols/administration & dosage , Ethylene Glycols/pharmacokinetics , Female , Humans , Male , Proof of Concept Study
12.
PLoS One ; 13(10): e0205263, 2018.
Article En | MEDLINE | ID: mdl-30379831

OBJECTIVES: The United States National Institute for Occupational Safety and Health (NIOSH) is developing a protocol to assess the containment performance of closed system transfer devices (CSTDs) when used for drug preparation (task 1) and administration (task 2) and published a draft protocol in September 2016. Nine possible surrogates were proposed by NIOSH for use in the testing. The objectives of this study were to: (A) select the most appropriate surrogate; (B) validate the NIOSH protocol using this surrogate; and (C) determine the containment performance of four commercial CSTDs as compared with an open system of needle and syringe using the validated NIOSH protocol. METHODS: 2-Phenoxyethanol (2-POE) was selected as a surrogate based on its water solubility, Henry's volatility constant, detectability by mass spectrometry, and non-toxicity. Standard analytical validation methods including system suitability, limit of detection (LOD), and limit of quantitation (LOQ) as well as system cleaning validation were performed. The amount of 2-POE released when the CSTDs were manipulated according to two tasks defined by NIOSH was determined using mass spectrometry coupled to thermal desorption and gas chromatography. This approach allows sensitivity of detection below 1 part per billion (ppb). Equashield, Tevadaptor (OnGuard), PhaSeal, and ChemoClave were assessed according to manufacturers' instructions for use. RESULTS: 2-POE was tested and validated for suitability of use within the NIOSH protocol. A simple and efficient cleaning protocol achieved consistently low background values, with an average value, based on 85 measurements, of 0.12 ppb with a 95% confidence interval (CI) of ±0.16 ppb. This gives an LOD for the tests of 0.35 ppb and an LOQ of 0.88 ppb. The Equashield, Tevadaptor (OnGuard), and PhaSeal devices all showed average releases, based on 10 measurements from five tests, that were less than the LOQ (i.e. < 0.88 ppb), while the ChemoClave Vial Shield with Spinning Spiros showed average releases of 2.9±2.3 ppb and 7.5±17.9 ppb for NIOSH tasks 1 and 2 respectively at the 95% confidence level. The open system of needle and syringe showed releases, based on two measurements from a single test, of 4.2±2.2 ppb and 5.1±1.7 ppb for NIOSH tasks 1 and 2 respectively at the 95% confidence level. CONCLUSIONS: 2-POE proved to be an ideal surrogate for testing of CSTDs using the NIOSH protocol. We propose that a CSTD can be qualified using the NIOSH testing approach if the experimental LOQ is less than 1 ppb and the release values are below the LOQ. Equashield, Tevadaptor (OnGuard), and PhaSeal meet these acceptance criteria and can therefore all be qualified as CSTDs, but the ChemoClave system does not and so would not qualify as a CSTD.


Drug Compounding/instrumentation , Drug Delivery Systems/instrumentation , Occupational Exposure/prevention & control , Protective Devices , Ethylene Glycols/administration & dosage , Ethylene Glycols/chemistry , Gas Chromatography-Mass Spectrometry , Guidelines as Topic , Humans , Needles , Occupational Exposure/standards , Pharmaceutical Services/standards , Research Design , Syringes , United States
13.
Eur J Pharm Sci ; 125: 223-231, 2018 Dec 01.
Article En | MEDLINE | ID: mdl-30316975

Imiquimod (IMQ) is an immunostimulant drug topically used for the treatment of actinic keratosis and basal cell carcinoma. IMQ formulation and skin delivery is difficult because of its very low solubility in the most of pharmaceutical excipients and very poor skin penetration properties. The purpose of this study was to develop a microemulsion to optimize imiquimod skin delivery using d­α­tocopherol polyethylene glycol-1000 succinate (TPGS) as surfactant (so as to take advantage of its thickening properties) and isostearic acid as oil phase. This fatty acid was selected since it has demonstrated a good solubilizing power for imiquimod and it has also shown to contribute to its therapeutic activity. We have built pseudo-ternary diagrams using two different co-surfactants (Transcutol® and propylene glycol - PG) in a 1:1 ratio with TPGS and then selected microemulsions in the clear and viscous regions of the diagrams. The systems were characterized in terms of rheology and X-ray scattering; additionally, the capability to promote IMQ skin uptake was evaluated ex-vivo on a porcine skin model. All the formulations selected in the gel-microemulsion regions behaved as viscoelastic solids; X-rays scattering experiments revealed in all cases the presence of an ordered lamellar structure, but with differences in terms of interlamellar distance and flexibility between Transcutol® and PG-containing systems. A higher flexibility and a greater hydrophobic volume, possibly interconnected at some point, was associated to the use of Transcutol® and had an impact on the microemulsion capacity to solubilize IMQ as well as on the capability to enhance drug uptake into the skin. The best performing gel-like microemulsion was composed of ≈26% of water, ≈21% of isostearic acid, ≈26% of TPGS and ≈27% of Transcutol® and accumulated, after 6 h of contact, 3.0 ±â€¯1.1 µg/cm2 of IMQ. This value is higher than the one reported in the literature for the commercial cream (1.9 ±â€¯0.8 µg/cm2), despite the 4-times lower concentration of the vehicle (13 mg/g for the microemulsion vs 50 mg/g for the commercial cream).


Adjuvants, Immunologic/chemistry , Antineoplastic Agents/chemistry , Imiquimod/chemistry , Surface-Active Agents/chemistry , Vitamin E/chemistry , Adjuvants, Immunologic/administration & dosage , Administration, Cutaneous , Animals , Antineoplastic Agents/administration & dosage , Chemistry, Pharmaceutical , Emulsions , Ethylene Glycols/administration & dosage , Ethylene Glycols/chemistry , Imiquimod/administration & dosage , Propylene Glycol/administration & dosage , Propylene Glycol/chemistry , Skin/metabolism , Skin Absorption , Stearic Acids/administration & dosage , Stearic Acids/chemistry , Surface-Active Agents/administration & dosage , Swine , Vitamin E/administration & dosage
14.
Drug Dev Ind Pharm ; 44(10): 1642-1649, 2018 Oct.
Article En | MEDLINE | ID: mdl-29851521

OBJECTIVE: The aim of this study was to develop a drug-in-adhesive patch for transdermal delivery of daphnetin (DA), which is a coumarin derivative in Girald Daphne, and to investigate the role of Transcutol P (TP) in the release and percutaneous permeation processes of DA. METHODS: Backing films, permeation enhancers and enhancer content in the transdermal patch were investigated through in vitro experiments using rat skin. Anti-inflammatory and analgesic effects of the optimized formulation were evaluated using the adjuvant arthritis model and the pain model induced by acetic acid, respectively. In addition, the enhancement effect of TP was investigated using differential scanning calorimetry (DSC), FTIR, and molecular dynamic simulation. RESULTS: The optimal formulation, composed of DURO-TAK® 87-2852, CoTranTM 9680, 1% DA, and 10% TP showed anti-inflammatory and analgesic effects. It was found that TP only promoted the release process of DA from its transdermal patch. Furthermore, the decrease of interaction between drug and pressure sensitive adhesive (PSA) as well as the improvement of PSA mobility due to TP addition were the main factors that enhanced the release of DA from patch. CONCLUSIONS: This study successfully used TP to develop a DA patch with good anti-inflammatory and analgesic effects, proving that TP promotes the release of DA by reducing the interaction between DA and PSA and increasing the mobility of PSA.


Ethylene Glycols/chemical synthesis , Ethylene Glycols/pharmacokinetics , Skin Absorption/drug effects , Transdermal Patch , Umbelliferones/chemical synthesis , Umbelliferones/pharmacokinetics , Administration, Cutaneous , Animals , Ethylene Glycols/administration & dosage , Male , Mice , Rats , Rats, Wistar , Skin Absorption/physiology , Umbelliferones/administration & dosage
15.
Exp Gerontol ; 108: 226-230, 2018 07 15.
Article En | MEDLINE | ID: mdl-29704641

BACKGROUND: Inflammation promotes amyloidogenesis in animals and markers of inflammation are associated with ß-amyloid (Aß) in humans. Hence, we sought to examine the cross-sectional associations between chronically elevated plasma C reactive protein (CRP) and cortical Aß in 259 non-demented elderly individuals reporting subjective memory complaints from the Multidomain Alzheimer Preventive Trial (MAPT). METHODS: Cortical-to-cerebellar standard uptake value ratios were obtained using [18F] florbetapir positron emission tomography (PET). CRP was measured in plasma using immunoturbidity. Chronically raised CRP was defined as having 2 consecutively high CRP readings (>3 mg/l ≤ 10 mg/l) between study baseline and the 1 year visit (visits were performed at baseline, 6 months, 1 year and then annually). Associations were explored using adjusted multiple linear regression. RESULTS: Chronically raised CRP was found to be inversely associated with cortical Aß (B-coefficient: -0.054, SE: 0.026, p = 0.040) and this association seemed to be specific to apolipoprotein E (Apo E) ε4 carriers (B-coefficient: -0.130, SE: 0.058, p = 0.027). CRP as an isolated reading measured closest to PET scan was also inversely associated with cortical Aß when CRP was treated as a dichotomized variable (high CRP > 3 mg/l ≤ 10 mg/l, B-coefficient: -0.048, SE: 0.023, p = 0.043). CONCLUSIONS: Our preliminary findings suggest that inflammation might be beneficial in the early stages of Alzheimer's disease as the immune systems attempts to combat Aß pathology particularly in ApoE ε4 carriers. Investigating the temporal relationships between cerebral Aß and a panel of inflammatory markers would provide further evidence as to whether chronic inflammation might modulate amyloidogenesis in vivo.


Alzheimer Disease/physiopathology , Alzheimer Disease/psychology , Amyloid beta-Peptides/analysis , C-Reactive Protein/analysis , Cerebral Cortex/chemistry , Memory Disorders/physiopathology , Aged , Aged, 80 and over , Alzheimer Disease/genetics , Aniline Compounds/administration & dosage , Apolipoprotein E4/genetics , Cerebellum/chemistry , Cognition , Cross-Sectional Studies , Ethylene Glycols/administration & dosage , Female , Heterozygote , Humans , Inflammation , Linear Models , Male , Memory , Neuropsychological Tests , Positron-Emission Tomography
16.
Int J Med Sci ; 15(5): 498-506, 2018.
Article En | MEDLINE | ID: mdl-29559839

Objective: To construct carcinoma vascular endothelial-targeted polymeric nanomicelles with high magnetic resonance imaging (MRI) sensitivity and to evaluate their biological safety and in vitro tumor-targeting effect, and to monitor their feasibility using clinical MRI scanner. Method: Amphiphilic block copolymer, poly(ethylene glycol)-b-poly(ε-caprolactone) (PEG-PCL) was synthesized via the ring-opening polymerization of ε-caprolactone (CL) initiated by poly(ethylene glycol) (PEG), in which cyclic pentapeptide Arg-Gly-Asp (cRGD) was conjugated with the terminal of hydrophilic PEG block. During the self-assembly of PEG-PCL micelles, superparamagnetic γ-Fe2O3 nanoparticles (11 nm) was loaded into the hydrophobic core. The cRGD-terminated γ-Fe2O3-loaded polymeric micelles targeting to carcinoma vascular endothelial cells, were characterized in particle size, morphology, loading efficiency and so on, especially high MRI sensitivity in vitro. Normal hepatic vascular endothelial cells (ED25) were incubated with the resulting micelles for assessing their safety. Human hepatic carcinoma vascular endothelial cells (T3A) were cultured with the resulting micelles to assess the micelle uptake using Prussian blue staining and the cell signal intensity using MRI. Results: All the polymeric micelles exhibited ultra-small particle sizes with approximately 50 nm, high relaxation rate, and low toxicity even at high iron concentrations. More blue-stained iron particles were present in the targeting group than the non-targeting and competitive inhibition groups. In vitro MRI showed T2WI and T2 relaxation times were significantly lower in the targeting group than in the other two groups. Conclusion: γ-Fe2O3-loaded PEG-PCL micelles not only possess ultra-small size and high superparamagnetic sensitivity, also can be actively targeted to carcinoma vascular endothelial cells by tumor-targeted cRGD. It appears to be a promising contrast agent for tumor-targeted imaging.


Carcinoma/diagnostic imaging , Contrast Media/administration & dosage , Ethylene Glycols/administration & dosage , Liver Neoplasms/diagnostic imaging , Polyesters/administration & dosage , Carcinoma/pathology , Cell Line, Tumor , Contrast Media/chemistry , Endothelial Cells/drug effects , Endothelial Cells/pathology , Ethylene Glycols/chemistry , Ferric Compounds/administration & dosage , Ferric Compounds/chemistry , Humans , Liver Neoplasms/physiopathology , Magnetic Resonance Imaging , Magnetite Nanoparticles/administration & dosage , Magnetite Nanoparticles/chemistry , Micelles , Particle Size , Polyesters/chemistry
17.
Drug Deliv Transl Res ; 8(3): 670-692, 2018 06.
Article En | MEDLINE | ID: mdl-29589250

The work describes systematic development of nanomicellar cationic supersaturable self-nanoemulsifying drug delivery systems (CS-SNEDDS) for augmenting oral biopharmaceutical performance of raloxifene hydrochloride. Plain SNEDDS formulation containing Capryol 90, Cremophor RH 40, and Transcutol HP was optimized using D-optimal mixture design. SNEDDS were characterized for emulsification time, globule size, in vitro drug release, and ex vivo permeation. The CS-SNEDDS formulation was prepared from the optimized SNEDDS by adding oleylamine as the cationic charge inducer and HPMC as the polymeric precipitation inhibitor. Evaluation of CS-SNEDDS was carried out through in vitro cell line studies on Caco-2 and MCF-7 cells, in situ perfusion, and in vivo pharmacokinetic studies, which indicated significant improvement in biopharmaceutical attributes of the drug from CS-SNEDDS over plain drug.


Drug Delivery Systems , Estrogen Antagonists/administration & dosage , Ethylene Glycols/administration & dosage , Nanoparticles/administration & dosage , Polyethylene Glycols/administration & dosage , Polymers/administration & dosage , Propylene Glycols/administration & dosage , Raloxifene Hydrochloride/administration & dosage , Animals , Biological Transport , Caco-2 Cells , Cell Survival/drug effects , Chemistry, Pharmaceutical , Drug Liberation , Emulsions , Estrogen Antagonists/chemistry , Estrogen Antagonists/pharmacokinetics , Ethylene Glycols/chemistry , Ethylene Glycols/pharmacokinetics , Humans , Hypromellose Derivatives/chemistry , Intestinal Mucosa/metabolism , MCF-7 Cells , Micelles , Models, Biological , Nanoparticles/chemistry , Polyethylene Glycols/chemistry , Polyethylene Glycols/pharmacokinetics , Polymers/chemistry , Polymers/pharmacokinetics , Propylene Glycols/chemistry , Propylene Glycols/pharmacokinetics , Raloxifene Hydrochloride/chemistry , Raloxifene Hydrochloride/pharmacokinetics , Rats, Sprague-Dawley
18.
Drug Dev Ind Pharm ; 44(6): 873-885, 2018 Jun.
Article En | MEDLINE | ID: mdl-29254384

OBJECTIVE: The aim of the study was to design a self-emulsifying drug delivery system (SEDDS) of the anti-hypertensive Carvedilol in liquid and liquisolid forms as a way to enhance its dissolution profile and anti-hypertensive effect. METHODS: Solubility studies of Carvedilol in various oils, surfactants and co-surfactants were conducted, followed by the construction of pseudo-ternary phase diagrams and other in vitro assessments. The selected SEDDS formulation (S1) was adsorbed onto solid powder excipients and compressed into tablets. The resulting liquisolid tablets were evaluated under British Pharmacopoeia (B.P.) specifications. Pre- and post-compression studies were performed to determine the flow properties and evaluate the liquisolid systems, followed by in vivo studies in hypertensive rats. RESULTS: Attempts of self-emulsification, droplet size, and thermodynamic stability studies showed acceptable results for the S1 formulation containing Capryol 90, Tween 20, and Transcutol HP (10:53.3:26.2%), respectively. Pre-compression studies showed adequate flowability and compatibility of liquid and solid excipients with Carvedilol. The selected liquisolid tablet (LS7) demonstrated the best disintegration and water absorption ratio in addition to satisfactory friability and hardness. A significantly (p < .05) fast dissolution rate was observed for both SEDDS and liquisolid formulations when compared to pure drug and marketed Carvepress®. The in vivo study of LS7 formulation revealed a rapid significant (p < .01) decrease in the mean arterial pressure (MAP) of the rats (112.72 mmHg) within the first 30 min followed by a further decline (107.22 mmHg) after 1 h when compared to Carvepress®. CONCLUSION: Self-emulsifying liquisolid tablets expressed rapid onset of action with enhanced anti-hypertensive effect of Carvedilol.


Antihypertensive Agents/administration & dosage , Carbazoles/pharmacology , Emulsions/chemistry , Ethylene Glycols/administration & dosage , Polymers/chemistry , Polysorbates/chemistry , Propanolamines/pharmacology , Propylene Glycols/chemistry , Surface-Active Agents/chemistry , Animals , Antihypertensive Agents/chemistry , Antihypertensive Agents/pharmacology , Carbazoles/administration & dosage , Carbazoles/chemistry , Carvedilol , Chemistry, Pharmaceutical , Drug Delivery Systems , Ethylene Glycols/chemistry , Ethylene Glycols/pharmacology , Excipients , Propanolamines/administration & dosage , Propanolamines/chemistry , Rats , Solubility , Tablets
19.
J Toxicol Sci ; 42(6): 707-713, 2017.
Article En | MEDLINE | ID: mdl-29142169

Ethylene glycol monomethyl ether (EGME), which is widely used in various industrial products, is known for adverse effects on the reproductive system in adult rats. However, the effects of EGME on reproductive development in juvenile rats have not been demonstrated. In order to investigate the effects of EGME on the female reproductive system and pubertal development in juvenile rats, EGME was administered to female Sprague Dawley rats from postnatal day 21 to 41 at a dose level of 0, 50, 100, or 300 mg/kg. The animals were examined for general condition, body weight, vaginal opening (VO), estrous cyclicity, and histopathology of reproductive organs. EGME treatment resulted in a prolonged estrous cycle interval characterized by persistent diestrus at 50 mg/kg without effects on body weight, timing of VO, or histology of the reproductive organs. EGME at 100 mg/kg induced decreases in body weight gain, a delay of VO, and irregular estrous cycle with absence of corpora lutea and hypertrophy of uterine epithelium indicating disturbance of the ovulatory process associated with hormonal effect. At 300 mg/kg, there was significant delay of puberty due to severe growth retardation. The present results revealed that irregular estrous cycle is a first indicator of the effects of EGME on the female reproductive system in juvenile rats, with delayed pubertal onset and ovulatory process disturbance at a higher dose.


Ethylene Glycols/adverse effects , Ethylene Glycols/toxicity , Reproduction/drug effects , Animals , Corpus Luteum/drug effects , Dose-Response Relationship, Drug , Estrous Cycle/drug effects , Ethylene Glycols/administration & dosage , Female , Ovulation/drug effects , Pregnancy , Puberty/drug effects , Rats, Sprague-Dawley , Weight Gain/drug effects
20.
Eur J Pharm Sci ; 109: 297-315, 2017 Nov 15.
Article En | MEDLINE | ID: mdl-28842349

Development of self-nanoemulsifying drug delivery systems (SNEDDS) of polypeptide-k (PPK) is reported with the aim to achieve its oral delivery. Box-Behnken design (BBD) was adopted to develop and optimize the composition of SNEDDS. Oleoyl polyoxyl-6 glycerides (A), Tween 80 (B), and diethylene glycol monoethyl ether (C) were used as oil, surfactant and co-surfactant, respectively as independent variables. The effect of variation in their composition was observed on the mean droplet size (y1), polydispersity index (PDI) (y2), % drug loading (y3) and zeta potential (y4). As per the optimal design, seventeen SNEDDS prototypes were prepared. The optimized composition of SNEDDS formulation was 25% v/v Oleoyl polyoxyl-6 glycerides, 37% v/v Tween 80, 38% v/v diethylene glycol monoethyl ether, and 3% w/v PPK. The optimized formulation revealed values of y1, y2, y3, and y4 as 31.89nm, 0.16, 73.15%, and -15.65mV, respectively. Further the optimized liquid SNEDDS were solidified through spray drying using various hydrophilic and hydrophobic carriers. Among the various carriers, Aerosil 200 was found to provide desirable flow, compression, disintegration and dissolution properties. Both, liquid and solid-SNEDDS have shown release of >90% within 10min. The formulation was found stable with change in pH, dilution, temperature variation and freeze thaw cycles in terms of droplet size, zeta potential, drug precipitation and phase separation. Crystalline PPK was observed in amorphous state in solid SNEDDS when characterized through DSC and PXRD studies. The biochemical, hematological and histopathological results of streptozotocin induced diabetic rats shown promising antidiabetic potential of PPK loaded in SNEDDS at its both the doses (i.e. 400mg/kg and 800mg/kg) as compared to its naïve form at both the doses. The study revealed successful formulation of SNEDDS for oral delivery of PPK.


Diabetes Mellitus, Experimental/drug therapy , Hypoglycemic Agents/administration & dosage , Nanostructures/administration & dosage , Peptides/administration & dosage , Administration, Oral , Alanine Transaminase/blood , Animals , Aspartate Aminotransferases/blood , Blood Glucose/drug effects , Body Weight/drug effects , Catalase/metabolism , Chemistry, Pharmaceutical , Diabetes Mellitus, Experimental/blood , Diabetes Mellitus, Experimental/metabolism , Diabetes Mellitus, Experimental/pathology , Drug Delivery Systems , Drug Liberation , Emulsions , Ethylene Glycols/administration & dosage , Ethylene Glycols/chemistry , Ethylene Glycols/therapeutic use , Hypoglycemic Agents/chemistry , Hypoglycemic Agents/therapeutic use , Liver/drug effects , Liver/metabolism , Male , Nanostructures/chemistry , Nanostructures/therapeutic use , Pancreas/drug effects , Pancreas/pathology , Peptides/chemistry , Peptides/therapeutic use , Polyethylene Glycols/administration & dosage , Polyethylene Glycols/chemistry , Polyethylene Glycols/therapeutic use , Polysorbates/administration & dosage , Polysorbates/chemistry , Polysorbates/therapeutic use , Rats, Wistar , Superoxide Dismutase/metabolism , Thiobarbituric Acid Reactive Substances/metabolism
...